These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20031949)

  • 1. A meta-analysis of erythropoiesis-stimulating agents in anaemic patients with chronic heart failure.
    Jin B; Luo X; Lin H; Li J; Shi H
    Eur J Heart Fail; 2010 Mar; 12(3):249-53. PubMed ID: 20031949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents.
    Lawler PR; Filion KB; Eisenberg MJ
    J Card Fail; 2010 Aug; 16(8):649-58. PubMed ID: 20670844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials.
    Kang J; Park J; Lee JM; Park JJ; Choi DJ
    Int J Cardiol; 2016 Sep; 218():12-22. PubMed ID: 27209352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summaries of nursing care-related systematic reviews from the Cochrane library: erythropoiesis-stimulating agents for anemia in chronic heart failure patients.
    Barrett D
    J Cardiovasc Nurs; 2010; 25(5):381-2. PubMed ID: 20714234
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents and heart failure.
    Lipšic E; van der Meer P; van Veldhuisen DJ
    Cardiovasc Ther; 2011 Aug; 29(4):e52-9. PubMed ID: 20973926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaemia in older people with chronic heart failure: The potential cost.
    Man-Fai Sim V; Nam MC; Riley S; Yousef Z; Hurley J; Cheung WY; O'Mahony S
    Technol Health Care; 2009; 17(5-6):377-85. PubMed ID: 20051617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future directions in management of anemia in heart failure.
    Agarwal AK; Katz SD
    Heart Fail Clin; 2010 Jul; 6(3):385-95. PubMed ID: 20630412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Erythropoiesis-stimulating agents in congestive heart failure patients].
    Robles Perez-Monteoliva NR; Macías Núñez JF; Herrera Pérez de Villar J
    Med Clin (Barc); 2014 Mar; 142(5):215-8. PubMed ID: 24012446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
    Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
    Anaya S; Rivera F; Sánchez de la Nieta MD; Carreño A; Vozmediano C; Alcaide MP; Arambarri M; Nieto J; Caparrós G; Ferreras I
    Nefrologia; 2008; 28(2):186-92. PubMed ID: 18454709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia and cardiovascular risk in the patient with kidney disease.
    Fishbane S
    Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating anemia in heart failure patients: a review of erythropoiesis-stimulating agents.
    Geisler BP
    Expert Opin Biol Ther; 2010 Aug; 10(8):1209-16. PubMed ID: 20557272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes.
    Agarwal AK; Singh AK
    Heart Fail Clin; 2010 Jul; 6(3):323-32. PubMed ID: 20630407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CERA: third-generation erythropoiesis-stimulating agent.
    Topf JM
    Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comorbidity: anemia and heart failure].
    Mahfoud F; Kindermann I; Kindermann M; Ukena C; Böhm M
    Dtsch Med Wochenschr; 2009 Apr; 134(16):825-30. PubMed ID: 19353467
    [No Abstract]   [Full Text] [Related]  

  • 16. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
    Moossavi S; Freedman BI
    Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
    [No Abstract]   [Full Text] [Related]  

  • 17. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erythropoesis-stimulating agents: past, present and future].
    Kes P; Basić-Jukić N
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis.
    Tehrani F; Dhesi P; Daneshvar D; Phan A; Rafique A; Siegel RJ; Cercek B
    Cardiovasc Drugs Ther; 2009 Dec; 23(6):511-8. PubMed ID: 19862609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia in chronic heart failure.
    Drakos SG; Anastasiou-Nana MI; Malliaras KG; Nanas JN
    Congest Heart Fail; 2009; 15(2):87-92. PubMed ID: 19379455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.